Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

TirzepatideSemaglutideRetatrutideLiraglutide

Dimension	Tirzepatide Mounjaro	Semaglutide Ozempic	Retatrutide LY3437943	Liraglutide Saxenda
Evidence tier	AHuman RCT evidence	AHuman RCT evidence	AHuman RCT evidence	AHuman RCT evidence
Intelligence Score™	6.5/ 10 · Moderate	8.0/ 10 · Strong	6.5/ 10 · Moderate	6.5/ 10 · Moderate
Family	GIP / GLP-1 dual agonist	GLP-1 receptor agonist	GIP / GLP-1 / glucagon triple agonist	GLP-1 receptor agonist
Half-life	~5 days	~7 days	~6 days	~13 h
Typical dose	2.5–15 mg/week, titrated	0.25–2.4 mg/week, titrated	1–12 mg/week (trial)	0.6–3.0 mg/day
Routes	Subcutaneous	Subcutaneous, Oral	Subcutaneous	Subcutaneous
Tier label	Human RCT	Human RCT	Human RCT	Human RCT
Mechanism	Co-agonist at GIP and GLP-1 receptors; delays gastric emptying, modulates appetite and glucose homeostasis.	Agonist at the GLP-1 receptor; delays gastric emptying, increases glucose-dependent insulin secretion, suppresses appetite via central pathways.	Co-agonism at GIP, GLP-1, and glucagon receptors.	GLP-1 receptor agonist; albumin-binding extends half-life relative to native GLP-1.
Reported uses	weight-management	weight-management, addiction-cravings, eating-disorders	weight-management	weight-management
Contraindications	— MTC — MEN-2 — Pregnancy	— Personal/family MTC — MEN-2 — Pregnancy — History of pancreatitis (caution)	— Investigational — clinical trial only	— MTC — MEN-2 — Pregnancy
Citations	1	1	1	1

AHuman RCT evidence

Intelligence Score™: 6.5/ 10 · Moderate
Family: GIP / GLP-1 dual agonist
Half-life: ~5 days
Typical dose: 2.5–15 mg/week, titrated
Routes: Subcutaneous
Tier label: Human RCT
Mechanism: Co-agonist at GIP and GLP-1 receptors; delays gastric emptying, modulates appetite and glucose homeostasis.
Reported uses: weight-management
Contraindications: — MTC
— MEN-2
— Pregnancy
Citations: 1

AHuman RCT evidence

Intelligence Score™: 8.0/ 10 · Strong
Family: GLP-1 receptor agonist
Half-life: ~7 days
Typical dose: 0.25–2.4 mg/week, titrated
Routes: Subcutaneous, Oral
Tier label: Human RCT
Mechanism: Agonist at the GLP-1 receptor; delays gastric emptying, increases glucose-dependent insulin secretion, suppresses appetite via central pathways.
Reported uses: weight-management, addiction-cravings, eating-disorders
Contraindications: — Personal/family MTC
— MEN-2
— Pregnancy
— History of pancreatitis (caution)
Citations: 1

AHuman RCT evidence

AHuman RCT evidence

Intelligence Score™: 6.5/ 10 · Moderate
Family: GLP-1 receptor agonist
Half-life: ~13 h
Typical dose: 0.6–3.0 mg/day
Routes: Subcutaneous
Tier label: Human RCT
Mechanism: GLP-1 receptor agonist; albumin-binding extends half-life relative to native GLP-1.
Reported uses: weight-management
Contraindications: — MTC
— MEN-2
— Pregnancy
Citations: 1

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.